CN108135886A - 用于糖尿病性肾病治疗的pde4抑制剂 - Google Patents

用于糖尿病性肾病治疗的pde4抑制剂 Download PDF

Info

Publication number
CN108135886A
CN108135886A CN201680056550.2A CN201680056550A CN108135886A CN 108135886 A CN108135886 A CN 108135886A CN 201680056550 A CN201680056550 A CN 201680056550A CN 108135886 A CN108135886 A CN 108135886A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
angiotensin
phosphodiesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680056550.2A
Other languages
English (en)
Chinese (zh)
Inventor
G.哈瑙尔
S.福莱特
波佐間·正聡
松尾·孝徳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of CN108135886A publication Critical patent/CN108135886A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680056550.2A 2015-07-29 2016-07-28 用于糖尿病性肾病治疗的pde4抑制剂 Pending CN108135886A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562198213P 2015-07-29 2015-07-29
US62/198213 2015-07-29
PCT/EP2016/067968 WO2017017165A1 (en) 2015-07-29 2016-07-28 Pde4 inhibitor for the treatment of diabetic nephropathy

Publications (1)

Publication Number Publication Date
CN108135886A true CN108135886A (zh) 2018-06-08

Family

ID=56551407

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680056550.2A Pending CN108135886A (zh) 2015-07-29 2016-07-28 用于糖尿病性肾病治疗的pde4抑制剂

Country Status (9)

Country Link
US (1) US20200179369A1 (enExample)
EP (1) EP3328381A1 (enExample)
JP (1) JP2018521077A (enExample)
CN (1) CN108135886A (enExample)
BR (1) BR112018001116A2 (enExample)
CA (1) CA2992796A1 (enExample)
EA (1) EA201890346A1 (enExample)
MA (1) MA42519A (enExample)
WO (1) WO2017017165A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110099686A (zh) * 2016-08-26 2019-08-06 武田有限公司 非酒精性脂肪性肝病的治疗

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115887460A (zh) * 2017-05-27 2023-04-04 青岛海蓝医药有限公司 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用
CN114053281B (zh) * 2020-08-10 2025-05-27 成都文鼎科技发展有限公司 治疗慢性肾病的方法和药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187269A1 (en) * 2004-02-25 2005-08-25 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US8324391B2 (en) * 2004-03-03 2012-12-04 Nycomed Gmbh Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1438027A1 (en) * 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187269A1 (en) * 2004-02-25 2005-08-25 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US8324391B2 (en) * 2004-03-03 2012-12-04 Nycomed Gmbh Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KULBHUSHAN TIKOO等: "Calorie restriction mimicking effects of roflumilast prevents diabetic nephropathy", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110099686A (zh) * 2016-08-26 2019-08-06 武田有限公司 非酒精性脂肪性肝病的治疗

Also Published As

Publication number Publication date
EP3328381A1 (en) 2018-06-06
BR112018001116A2 (pt) 2018-09-11
WO2017017165A1 (en) 2017-02-02
CA2992796A1 (en) 2017-02-02
MA42519A (fr) 2018-06-06
JP2018521077A (ja) 2018-08-02
EA201890346A1 (ru) 2018-08-31
US20200179369A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
JP6337170B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
CN108135886A (zh) 用于糖尿病性肾病治疗的pde4抑制剂
US20210106564A1 (en) Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
TW202216147A (zh) 用於治療內皮素相關疾病之齊泊騰坦和達格列淨的組合
NASEEMULLAH SIDDIQUI et al. ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR (CAPTOPRIL) IN PROTEINURIA, GLOMERULAR FILTRATION RATE AND LIPID PROFILE IN NIDDM PATIENTS

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180608

WD01 Invention patent application deemed withdrawn after publication